NCT07000877View on ClinicalTrials.gov

Nasal Decongestant to Reduce Perioperative Adverse Events in Children With Upper Respiratory Track Infections Having Anesthesia.

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

May 30, 2025

Primary Completion Date

May 30, 2028

Study Completion Date

May 30, 2028

Conditions
Perioperative Respiratory Adverse EventsAnesthesia Outcomes
Interventions
DRUG

Decongestant nasal spray (oxymetazoline hydrochloride (0.05%))

Decongestant nasal spray containing active ingredient.

DRUG

PLACEBO: 2.5mL of normal saline 0.9% and benzalkonium chloride 0.02%

Control nasal spray containing no active ingredient.

All Listed Sponsors
collaborator

Child and Adolescent Health Service - Perth

OTHER_GOV

collaborator

Hospital das Clínicas de São Paulo - SP

UNKNOWN

collaborator

Rigshospitalet, Denmark

OTHER

lead

Telethon Kids Institute

OTHER